People · Operator
Named in public records as an officer, director or promoter · active 2012–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Repros Therapeutics Inc. | — | Biotechnology | Series B | $29.5M | $936.7M | 2012 |
Daniel S. Cain at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel S. Cain on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael S. Wyllie, Ph.D. | 1 | 1 |
| Jean S. Fourcroy | 1 | 1 |
| Katherine S. Anderson | 1 | 1 |
| Jaye S. Thompson, Ph.D. | 1 | 1 |
| Joseph S. Podolski | 1 | 1 |
| Nola S. Masterson | 1 | 1 |
| Daniel F. Cain | 1 | 1 |
| Mark S. Lappe | 1 | 1 |
| Jean L. Fourcroy | 1 | 1 |
| Nola L. Masterson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.